Mirum Pharma’s Livmarli (maralixibat) gets FDA nod to treat cholestatic pruritus
Livmarli is the first drug to be approved by the US FDA for the treatment of cholestatic pruritus in young patients with the super rare Alagille syndrome (ALGS). Developed by California based Mirum Pharmaceuticals, Maralixibat is an IBAT inhibitor that reduces the absorption of circulating bile acid levels. Its mechanism of action would ultimately lower…
News Views